Fortis Healthcare Limited

14.2%

25 Fortis Healthcare announces Q4 FY25 and FY25 Financial Results Hospital Business Revenues up 14.2% for the quarter; 14.8% for the year Hospital business Op.EBITDA margins at 21.9% for the quarter;

14.8%

announces Q4 FY25 and FY25 Financial Results Hospital Business Revenues up 14.2% for the quarter; 14.8% for the year Hospital business Op.EBITDA margins at 21.9% for the quarter; 20.5% for the year B

21.9%

ness Revenues up 14.2% for the quarter; 14.8% for the year Hospital business Op.EBITDA margins at 21.9% for the quarter; 20.5% for the year Board recommends dividend of INR 1 per share (10% of Face Val

20.5%

for the quarter; 14.8% for the year Hospital business Op.EBITDA margins at 21.9% for the quarter; 20.5% for the year Board recommends dividend of INR 1 per share (10% of Face Value) Company acquires

INR 1

iness Op.EBITDA margins at 21.9% for the quarter; 20.5% for the year Board recommends dividend of INR 1 per share (10% of Face Value) Company acquires the perpetual Rights to the ‘Fortis’ Brand for INR

10%

argins at 21.9% for the quarter; 20.5% for the year Board recommends dividend of INR 1 per share (10% of Face Value) Company acquires the perpetual Rights to the ‘Fortis’ Brand for INR 200 Crs Q4 F

INR 200

R 1 per share (10% of Face Value) Company acquires the perpetual Rights to the ‘Fortis’ Brand for INR 200 Crs Q4 FY 25 Results • Consolidated Revenues up 12.4% to INR 2,007 Cr • Operating EBITDA up 14

12.4%

petual Rights to the ‘Fortis’ Brand for INR 200 Crs Q4 FY 25 Results • Consolidated Revenues up 12.4% to INR 2,007 Cr • Operating EBITDA up 14.3% to INR 435 Cr, 21.7% Margin (vs Q4FY24 at 21.3%) •

INR 2,007

ghts to the ‘Fortis’ Brand for INR 200 Crs Q4 FY 25 Results • Consolidated Revenues up 12.4% to INR 2,007 Cr • Operating EBITDA up 14.3% to INR 435 Cr, 21.7% Margin (vs Q4FY24 at 21.3%) • Hospital Busin

14.3%

0 Crs Q4 FY 25 Results • Consolidated Revenues up 12.4% to INR 2,007 Cr • Operating EBITDA up 14.3% to INR 435 Cr, 21.7% Margin (vs Q4FY24 at 21.3%) • Hospital Business Revenues up 14.2% to INR 1,7

INR 435

4 FY 25 Results • Consolidated Revenues up 12.4% to INR 2,007 Cr • Operating EBITDA up 14.3% to INR 435 Cr, 21.7% Margin (vs Q4FY24 at 21.3%) • Hospital Business Revenues up 14.2% to INR 1,701 Cr • Op

21.7%

lts • Consolidated Revenues up 12.4% to INR 2,007 Cr • Operating EBITDA up 14.3% to INR 435 Cr, 21.7% Margin (vs Q4FY24 at 21.3%) • Hospital Business Revenues up 14.2% to INR 1,701 Cr • Operating E

“By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.”

“Performance Highlights • Earnings and Financial Summary – Q4FY25 and FY25 3.”

“Appendix 4 CLINICAL EXCELLENCE AT FORTIS KEY HIGHLIGHTS 5 CLINICAL EXCELLENCE FY25 Performance – Key Procedures 67,400+ Cardiac Procedures1 30,500+ Joint Replacements and Other Ortho Procedures ~6,200 Robotic Surgeries3 1,000+ Transplants2 ~9,200 Neuro and Spine Surgeries 12,600+ Radiation Therapy Patients”

“Q1–Q3 FY25 • Fortis Hospital, Gurugram, performed the first-of-its-kind complex portal vein reconstruction by innovatively utilizing the umbilical vein on a 14-year-old child suffering from chronic Budd-Chiari Syndrome, a rare disorder affecting the liver and blood vessels.”

“EBITDA Reported PAT Hospital Business (INR Cr) 5,686 1,058 (18.6%) 11.3 14.8 7,783 1,588 (20.4%) % Revenue Growth YoY 809 FY25 6,528 1,339 (20.5%) (XX%) Op.”

“EBITDA margin % Revenue Growth YoY FY23-25 CAGR Revenue Op.”

“EBITDA 13.1% 24.6% FY24 FY25 Revenue Op.”

“Net Debt as on 31st Mar 2025 11 FY25 SNAPSHOT Consolidated Revenue Consolidated Op EBITDA Consolidated PBT1 7,783 Crores 12.9% 1,588 Crores (20.4% Margin) 25.3% 1,096 Crores 30.2% Consolidated PAT1 899 Crores 42.8% Net Debt / (Cash)3 Net Debt to EBITDA2,3 1,694 Crores 0.93x vs 0.17x Board recommends dividend of INR 1 per share (10% of face value); subject to shareholders’ approval 1.”

“Net Debt as on 31st Mar 2025 12 Key Updates Q4 FY25 ‘Fortis’ brand and trademarks Acquisition of Shrimann Hospital Mar’25/ Apr’25 : The company successfully acquired the ‘Fortis’ brand and trademarks through a public auction for a consideration of INR 200 Cr.”

“of Q1–Q3 FY25 Richmond Road Diagnostics Business Fortis Manesar Dec’24: Continuing with the portfolio rationalization strategy, the company divested business operations of the Richmond Road facility, Bangalore in Dec’24.”

Cash

2

For further details please contact

1

Note

1

For further details please contact

Anurag Kalra / Amit Mahendru Investor Relations +91-9810109253 / +91-9891094323 Ajey Maharaj Corporate Communication +91-9871798573 4 FORTIS HEALTHCARE LIMITED EARNINGS PRESENTATION – Q4 FY25 and FY25 May 20, 2025 1 DISCLAIMER This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy secu

Note

FY25 witnessed YoY growth across key procedures: Cardiac Procedures grew by 11%, Ortho Procedures by 9%, Robotic Surgeries by 72%, Radiation Therapy by 14%, and Neuro and Spine Procedures by 17% 1Cardiac Procedures include Cardiac Surgery, Angiography, Angioplasty and other Cardiology procedures 2Transplants include Kidney, Liver and Bone Marrow Transplants 3Robotic Surgeries include Cardiac, Urology, Oncology, Gynae, Ortho and General Surgery 6 CLINICAL EXCELLENCE Q4 FY25 • Fortis Escorts, Okhla Road, New Delhi, performed India’s first kidney auto-transplant on a 6-year-old boy from Uzbekistan with bilateral Wilms tumour—a rare kidney cancer—enabling precise tumour removal while minimizing the risk of cancer cell spread. Q1–Q3 FY25 • Fortis Hospital, Gurugram, performed the first-of-its-kind complex portal vein reconstruction by innovatively utilizing the umbilical vein on a 14-year-old child suffering from chronic Budd-Chiari Syndrome, a rare disorder affecting the liver and blood ve

Cash

Domestic, 34.3% Pvt Corps, 0.8% Govt & PSUs, 8.7% CGHS, 4.1% ECHS, 7.0% International , 8.0% Pvt Corps, 1.0% Govt & PSUs, 8.7% International , 7.8% CGHS, 4.5% ECHS, 7.4% 28 HOSPITAL BUSINESS PERFORMANCE – Q4FY25 & FY25 Key healthcare facilities continue to witness a YoY upward momentum in revenues Revenue Q4FY24 Q4FY25 262 207 203 178 172 133 146 135 140 129 125 115 135 117 95 83 52 60 66 53 All figures in INR Cr. FMRI Mohali Shalimar Bagh BG Road Noida Mulund FEHI Anandpur Faridabad Jaipur Revenue FY24 FY25 991 825 812 687 633 497 571 510 540 490 501 426 492 433 All figures in INR Cr. 352 302 198 235 245 231 FMRI Mohali Shalimar Bagh BG Road Noida Mulund FEHI Anandpur Faridabad Jaipur 29 HOSPITAL BUSINESS PERFORMANCE – FY25 Key hospitals witnessed healthy ARPOB and Occupancy growth 4.21 3.81 ARPOB (Rs Cr per annum) FY24 FY25 3.12 2.86 2.42 2.16 3.18 3.01 3.01 2.80 2.20 2.14 2.04 2.38 1.67 1.67 1.33 1.46 1.64 1.55 FMRI Mohali Shalimar Bagh BG Road Noida Mulund FEHI Anandpur Faridabad J